{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:50:21Z","timestamp":1760147421069,"version":"build-2065373602"},"reference-count":80,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Rare diseases affect less than 1 in 2000 people and are characterized by a serious, chronic, and progressive course. Among the described diseases, a mutation in a single gene caused mastocytosis, thrombotic thrombocytopenic purpura, Gaucher disease, and paroxysmal nocturnal hemoglobinuria (KIT, ADAMTS13, GBA1, and PIG-A genes, respectively). In Castleman disease, improper ETS1, PTPN6, TGFBR2, DNMT3A, and PDGFRB genes cause the appearance of symptoms. In histiocytosis, several mutation variants are described: BRAF, MAP2K1, MAP3K1, ARAF, ERBB3, NRAS, KRAS, PICK1, PIK3R2, and PIK3CA. Genes like HPLH1, PRF1, UNC13D, STX11, STXBP2, SH2D1A, BIRC4, ITK, CD27, MAGT1, LYST, AP3B1, and RAB27A are possible reasons for hemophagocytic lymphohistiocytosis. Among novel molecular medicines, tyrosine kinase inhibitors, mTOR inhibitors, BRAF inhibitors, interleukin 1 or 6 receptor antagonists, monoclonal antibodies, and JAK inhibitors are examples of drugs expanding therapeutic possibilities. An explanation of the molecular basis of rare diseases might lead to a better understanding of the pathogenesis and prognosis of the disease and may allow for the development of new molecularly targeted therapies.<\/jats:p>","DOI":"10.3390\/cells12030449","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T08:28:23Z","timestamp":1675067303000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9728-5281","authenticated-orcid":false,"given":"Gabriela","family":"R\u0119ka","sequence":"first","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, A. G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8036-8379","authenticated-orcid":false,"given":"Martyna","family":"Stefaniak","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, A. G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, A. G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1622","DOI":"10.1002\/mgg3.1622","article-title":"Novel frameshift mutation in PURA gene causes severe encephalopathy of unclear cause","volume":"9","author":"Spangenberg","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40257-020-00581-5","article-title":"Pediatric mastocytosis: Recognition and management","volume":"22","author":"Schaffer","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","first-page":"385","article-title":"Mastocytosis: A comprehensive insight","volume":"151","author":"Oranje","year":"2016","journal-title":"G Ital. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Guidelines for the diagnosis and treatment of cutaneous mastocytosis in children","volume":"12","author":"Castells","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","unstructured":"(2022, July 25). Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/index.php."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaci.2021.02.023","article-title":"Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis","volume":"148","author":"Teufelberger","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Martelli, M., Monaldi, C., De Santis, S., Bruno, S., Mancini, M., Cavo, M., and Soverini, S. (2020). Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113987"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.13231","article-title":"Abnormal bone marrow histopathology in paediatric mastocytosis","volume":"168","author":"Carter","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ajcp\/aqaa183","article-title":"Mastocytosis","volume":"155","author":"Tzankov","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/DAD.0b013e31826330bf","article-title":"Familial urticaria pigmentosa: Report of a family and review of the role of KIT mutations","volume":"35","author":"Fett","year":"2013","journal-title":"Am. J. Dermatopathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1525-1470.2011.01351.x","article-title":"Cutaneous mastocytosis in twins: Multiple mastocytomas and urticaria pigmentosa in two pairs of monozygotic twins","volume":"28","author":"Romero","year":"2011","journal-title":"Pediatr. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/17843286.2017.1293312","article-title":"Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: Diagnostic work-up of 38 patients","volume":"72","author":"Kochuyt","year":"2017","journal-title":"Acta Clin. Belg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/1346-8138.15764","article-title":"Diffuse cutaneous mastocytosis: Identification of KIT mutation and long-term follow-up with serum tryptase level","volume":"48","author":"Shibata","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"77","article-title":"Novel approaches to treating advanced systemic mastocytosis","volume":"11","author":"Gilreath","year":"2019","journal-title":"Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hoc.2017.09.005","article-title":"Diagnosis of Castleman disease","volume":"32","author":"Szalat","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman disease","volume":"32","author":"Wu","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.path.2019.03.003","article-title":"Castleman disease","volume":"12","author":"Wang","year":"2019","journal-title":"Surg. Pathol. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.6004\/jnccn.2019.5037","article-title":"Diagnosis and management of Castleman disease","volume":"17","author":"Abramson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_23","first-page":"625","article-title":"Clinical characteristics of 5 children with Castleman\u2019s disease and review of literature","volume":"48","author":"Huang","year":"2010","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hoc.2017.09.002","article-title":"Castleman disease pathogenesis","volume":"32","author":"Fajgenbaum","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_25","first-page":"697","article-title":"Progress in the diagnosis and treatment of Castleman disease","volume":"41","author":"Liu","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"Oksenhendler","year":"2020","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14397595.2019.1704983","article-title":"Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan","volume":"30","author":"Murakami","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas","volume":"2","author":"Nagy","year":"2018","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB mutations in unicentric Castleman disease","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2017.09.001","article-title":"Epidemiology of Castleman disease","volume":"32","author":"Simpson","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_31","unstructured":"(2022, July 25). Available online: https:\/\/www.omim.org\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","article-title":"Langerhans-cell histiocytosis","volume":"379","author":"Allen","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.revmed.2015.04.015","article-title":"Histiocytose langerhansienne de l\u2019adulte [Langerhans cell histiocytosis in adults]","volume":"36","author":"Artifoni","year":"2015","journal-title":"Rev. Med. Interne"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood.2019000934","article-title":"Langerhans cell histiocytosis","volume":"135","author":"Allen","year":"2020","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1111\/cas.13817","article-title":"Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment","volume":"109","author":"Kobayashi","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2017.05.060","article-title":"Langerhans cell histiocytosis in children: Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up","volume":"78","author":"Krooks","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102356","DOI":"10.1016\/j.bcmd.2019.102356","article-title":"BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival","volume":"82","author":"Bhatia","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_39","first-page":"132","article-title":"A prospective clinical multicentre study on adult pulmonary Langerhans\u2019 cell histiocytosis","volume":"29","author":"Dirks","year":"2012","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s12098-012-0719-7","article-title":"Clinical profile of Langerhans Cell Histiocytosis at a tertiary centre: A prospective study","volume":"79","author":"Uppal","year":"2012","journal-title":"Indian J. Pediatr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.hoc.2015.06.005","article-title":"Clinical characteristics and treatment of Langerhans cell histiocytosis","volume":"29","author":"Monsereenusorn","year":"2015","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/08880018.2018.1545814","article-title":"Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China","volume":"35","author":"Su","year":"2018","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sukumar, S., L\u00e4mmle, B., and Cataland, S.R. (2021). Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030536"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/jog.14737","article-title":"A successfully treated case of an acute presentation of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) with decreased ADAMTS13 during late stage of pregnancy","volume":"47","author":"Nonaka","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/16078454.2021.1945236","article-title":"Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP)\u2014Cognitive functioning and health-related quality of life impact: A descriptive cross-sectional survey of adults living with iTTP in the United Kingdom","volume":"26","author":"Holmes","year":"2021","journal-title":"Hematology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"546248","DOI":"10.3389\/fped.2020.546248","article-title":"Clinical features and gene mutation analysis of congenital thrombotic thrombocytopenic purpura in neonates","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/bloodadvances.2019000939","article-title":"Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sui","year":"2019","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4045\/tidsskr.15.1272","article-title":"Congenital thrombotic thrombocytopenic purpura","volume":"136","author":"Krogh","year":"2016","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/MPH.0000000000002032","article-title":"A case report of congenital thrombotic thrombocytopenic purpura: The peripheral blood smear lights the diagnosis","volume":"44","author":"Toret","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","article-title":"Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: Analysis of off-label use in Japan","volume":"112","author":"Kubo","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.151407","article-title":"Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: Interplay between genes and environmental triggers","volume":"103","author":"Ercig","year":"2018","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: An international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a subop-timal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.revmed.2018.11.012","article-title":"La maladie de Gaucher: Quand y penser? [Gaucher disease: A review]","volume":"40","author":"Nguyen","year":"2019","journal-title":"Rev. Med. Interne"},{"key":"ref_57","first-page":"72","article-title":"Gaucher disease: The metabolic defect, pathophysiology, phenotypes and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000440865","article-title":"Gaucher Disease: Clinical, Biological and Therapeutic Aspects","volume":"83","author":"Dandana","year":"2016","journal-title":"Pathobiology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher Disease in the era of choices","volume":"182","author":"Szer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: From pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: Progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/17512433.2018.1549486","article-title":"Pharmacological treatment of pediatric Gaucher disease","volume":"11","author":"Gupta","year":"2018","journal-title":"Exp. Rev. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1084\/jem.20190147","article-title":"A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function","volume":"216","author":"Lam","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e927087","DOI":"10.12659\/AJCR.927087","article-title":"Diagnosis of GATA2 deficiency in a young woman with hemophagocytic lymphohistiocytosis triggered by acute systemic cytomegalovirus infection","volume":"22","author":"Burak","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaci.2015.06.048","article-title":"Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry","volume":"137","author":"Cetica","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00005-014-0274-1","article-title":"Hemophagocytic syndrome in children and adults","volume":"62","author":"Malinowska","year":"2014","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10875-021-01025-3","article-title":"Diagnostic challenges in pediatric hemophagocytic lymphohistiocytosis","volume":"41","author":"Si","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"612583","DOI":"10.3389\/fimmu.2021.612583","article-title":"The spectrum of clinical, immunological, and molecular findings in familial hemophagocytic lymphohistiocytosis: Experience from India","volume":"12","author":"Shabrish","year":"2021","journal-title":"Front Immunol."},{"key":"ref_69","first-page":"e2838","article-title":"Hemophagocytic lymphohistiocytosis complicating systemic sarcoidosis","volume":"10","author":"Abughanimeh","year":"2018","journal-title":"Cureus"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/ACI.0000000000000405","article-title":"Comparing hemophagocytic lymphohistiocytosis in pediatric and adult patients","volume":"17","author":"Wysocki","year":"2017","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ejh.13593","article-title":"Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series","volume":"106","author":"Hansen","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_73","first-page":"e11956","article-title":"Paroxysmal nocturnal hemoglobinuria: A diagnostic \u201czero-sum-game\u201d","volume":"12","author":"Farooq","year":"2020","journal-title":"Cureus"},{"key":"ref_74","first-page":"341","article-title":"Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria","volume":"43","author":"Sandes","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1097\/MPH.0000000000001847","article-title":"Pediatric paroxysmal nocturnal hemoglobinuria presenting as acute kidney injury","volume":"43","author":"Henderson","year":"2021","journal-title":"J. Pediatr. Hematol Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Fattizzo, B., Serpenti, F., Giannotta, J.A., and Barcellini, W. (2021). Difficult cases of paroxysmal nocturnal hemoglobinuria: Diagnosis and therapeutic novelties. J. Clin. Med., 10.","DOI":"10.3390\/jcm10050948"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ajcp\/aqaa211","article-title":"Ultradeep sequencing analysis of paroxysmal nocturnal hemoglobinuria clones detected by flow cytometry: PIG mutation in small PNH clones","volume":"156","author":"Jeong","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MPH.0000000000002178","article-title":"Efficacy and safety of eculizumab for paroxysmal nocturnal hemoglobinuria: A systematic review and meta-analysis","volume":"43","author":"Zhou","year":"2021","journal-title":"J Pediatr. Hematol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13564","article-title":"One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab","volume":"106","author":"Kulasekararaj","year":"2021","journal-title":"Eur. J. Haematol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/3\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:20:09Z","timestamp":1760120409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/3\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cells12030449"],"URL":"https:\/\/doi.org\/10.3390\/cells12030449","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}